NaviFUS (ROCO:6872) Debt-to-Revenue : 7.33 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is NaviFUS Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

NaviFUS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$6.86 Mil. NaviFUS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$25.84 Mil. NaviFUS's annualized Revenue for the quarter that ended in Dec. 2023 was NT$4.46 Mil. NaviFUS's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 7.33.

NaviFUS Debt-to-Revenue Historical Data

The historical data trend for NaviFUS's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NaviFUS Debt-to-Revenue Chart

NaviFUS Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

0.01

1.45

NaviFUS Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial					N/A	0.05	0.01	0.89	7.33

Competitive Comparison of NaviFUS's Debt-to-Revenue

For the Biotechnology subindustry, NaviFUS's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NaviFUS's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NaviFUS's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where NaviFUS's Debt-to-Revenue falls into.

NaviFUS Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

NaviFUS's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(6.856	+	25.837)	/	22.481
	=	1.45

NaviFUS's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(6.856	+	25.837)	/	4.46
	=	7.33

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

NaviFUS Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of NaviFUS's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NaviFUS (ROCO:6872) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NaviFUS Corp (ROCO:6872) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.246, Sec 3, Chengde Road, 12th Floor, Datong District, Taipei City, TWN, 103

Website

https://www.navifus.com

NaviFUS Corp is a Biotech company providing novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery. Its product, the NaviFUS System, is designed to utilize non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision for better treatment outcomes. Its vision is to cater to CNS disease patients locally and globally by bringing therapeutic ultrasound technology to clinical use.

NaviFUS (ROCO:6872) Headlines

No Headlines